Clinical Trial Update: A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating furmonertinib in combination with radiotherapy for non-small cell lung cancer with oligoprogression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)
• Radiotherapy

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer, Oligoprogressive | Phase 2 | Status: UNKNOWN